Cannabis (medicinal) | Search results | NICE

Showing 1 to 13 of 13 results for cannabis (medicinal)

Sort by

Cannabis-based medicinal products (NG144)
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Result type
NICE guideline
Last updated
22 March 2021
View recommendations for NG144
Show all sections
Sections for NG144
What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with chemotherapy-induced nausea and vomiting which persists with optimised conventional antiemetics?
Question What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for...
Result type
Research recommendation
Published
10 February 2020
For children and young people with intractable cancer-related pain and pain associated with specific diseases (such as epidermolysis bullosa), what is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on to standard treatment to improve symptoms compared with treatment with standard care?
epidermolysis bullosa), what is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on to...
Result type
Research recommendation
Published
10 February 2020
What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment in babies, children and young people with chemotherapy-induced nausea or vomiting which persists with optimised conventional antiemetics?
Question What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment in...
Result type
Research recommendation
Published
10 February 2020
What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with persistent nausea or vomiting not caused by chemotherapy which hasn't fully responded to optimised conventional antiemetics?
Question What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for...
Result type
Research recommendation
Published
10 February 2020
What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for children, young people and adults with spasticity? In particular, what is the impact of spasticity on improvements in quality of life?
Question What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for...
Result type
Research recommendation
Published
10 February 2020
What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for babies, children and young people with persistent nausea or vomiting not caused by chemotherapy which hasn't fully responded to optimised conventional antiemetics?
Question What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for...
Result type
Research recommendation
Published
10 February 2020
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
Result type
NICE guideline
Published
7 April 2021
View recommendations for NG193
Show all sections
Sections for NG193
What is the clinical and cost effectiveness of CBD in epileptic disorders in children, young people and adults?
Why the committee made the research recommendationsThe only cannabis-based medicinal product available for the treatment...
Result type
Research recommendation
Published
10 February 2020
Does the addition of THC to CBD have an effect on seizure frequency, brain structure and neuropsychological performance when compared with both CBD alone and placebo in epileptic disorders in children, young people and adults?
Why the committee made the research recommendationsThe only cannabis-based medicinal product available for the treatment...
Result type
Research recommendation
Published
10 February 2020
For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of cannabidiol (CBD), containing no, or traces of, delta-9-tetrahydrocannabinol (THC), as an add-on to standard treatment?
evidence did not show a reduction in opioid use in people prescribed medicinal cannabis. Because the number of people who...
Result type
Research recommendation
Published
10 February 2020
Multiple sclerosis in adults: management (NG220)
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.
Result type
NICE guideline
Published
22 June 2022
View recommendations for NG220
Show all sections
Sections for NG220
Research recommendations
psychosis and coexisting substance misuse (for example, schizophrenia and cannabis misuse or bipolar disorder and alcohol misuse)?